Clinical trials: Carcinoma Breast
Breast Carcinoma
What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
This study explores why patients may want to receive real-time imaging results during a screening mammogram appointment at an MD Anderson breast imaging center.
- Trial name
- NCT04794816
- Testing
- Questionnaire Administration
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lymph Node Mapping
A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an…
- Conditions
- Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
- Trial name
- FILM-B (NCT03200704)
- Testing
- IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe
- Where
- 7 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Breast Cancer
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
In this research study we are studying the effects of the combination of lapatinib plus Herceptin in subjects with breast cancer that has spread outside of the breast.
- Trial name
- NCT00470704
- Testing
- Lapatinib, Herceptin
- Where
- 9 sites in United States
- Volunteers
- 87 people
- Sponsor
- Nancy Lin, MD
Breast Cancer
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE<10%) metastatic HER2-Low breast cancer.
- Trial name
- NCT06231693
- Testing
- Trastuzumab deruxtecan
- Where
- 2 sites in Brazil
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Breast Cancer
Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD)
Surgery and radiotherapy in breast cancer patients can cause treatment changes and may affect the final breast appearance. In this study, we are trying to evaluate the post treatment breast photographs of the patients and subject…
- Trial name
- ABCD (NCT05450016)
- Where
- India
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Centre
Rectal Neoplasms, Breast Neoplasms
Nano MRI on 7 Tesla in Rectal and Breast Cancer
This study evaluates the diagnostic accuracy of an USPIO contrast agent (ferumoxtran-10) in combination with 7 Tesla MRI to detect lymph node metastases in rectal and breast cancer.
- Trial name
- NCT02751606
- Testing
- ferumoxtran-10, 7 Tesla MRI, 3 Tesla MRI
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Breast Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer
- Trial name
- NCT01023204
- Testing
- Paclitaxel
- Volunteers
- 68 people
- Sponsor
- Bristol-Myers Squibb
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Breast Cancer, Cognitive/Functional Effects
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00303914
- Testing
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Where
- 32 sites in United States
- Volunteers
- 2,310 people
- Sponsor
- Eastern Cooperative Oncology Group
Recurrent Breast Cancer, Stage IV Breast Cancer
PS-341 in Treating Women With Metastatic Breast Cancer
PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
- Trial name
- NCT00025584
- Testing
- bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Sleep Disorders, Circadian Rhythm, Depression
Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy
Breast cancer is the second most common cancer in the world, the most common in women, representing the leading cause of death in Brazil.
- Conditions
- Sleep Disorders, Circadian Rhythm, Depression, Genotoxicity, Pain
- Trial name
- NCT03205033
- Testing
- Melatonin 20 MG Oral Capsule
- Volunteers
- 36 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
Breast Cancer
Adj TC + Herceptin Early Stage Breast Cancer
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
- Trial name
- NCT00493649
- Testing
- Taxotere, Cytoxan, Herceptin
- Where
- 69 sites in United States
- Volunteers
- 493 people
- Sponsor
- US Oncology Research
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal…
- Trial name
- proMONARCH (NCT03988114)
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
- Where
- 119 sites in United States, Argentina and 7 more
- Sponsor
- Eli Lilly and Company
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
This phase II trial compares leuprolide to goserelin for reducing estrogen production by the ovaries in pre- or peri-menopausal women with breast cancer. Estrogen can cause the growth of breast cancer cells.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT07158021
- Testing
- Biospecimen Collection, Electronic Health Record Review, Goserelin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Triple Negative Breast Cancer
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
The purpose of this study is to evaluate the efficacy and safety of Sintilimab plus anlotinib combined with chemotherapy as neoadjuvant therapy in participants who have triple negative breast cancer (TNBC).
- Trial name
- NeoSACT (NCT04877821)
- Testing
- Sintilimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Neoplasms
Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
At present, the majority of studies on neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) use pathological complete response (pCR) as a surrogate marker for patient prognosis, with significant improvements in pCR…
- Trial name
- NCT06856616
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- The Third Affiliated Hospital of Harbin Medical University
Breast Cancer Stage II, Breast Cancer Stage III
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients…
- Trial name
- Appalaches (NCT03609047)
- Testing
- Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide
- Where
- 73 sites in Belgium, France and 7 more
- Volunteers
- 366 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Acupressure for Cancer-Related Fatigue
This study develops and pilot tests the efficacy of a home-based, self-administered acupressure intervention in improving cancer-related fatigue (proximal outcome), and physical functioning and other quality of life outcomes…
- Trial name
- NCT03091647
- Testing
- acupressure intervention, usual care
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Georgetown University
ctDNA Monitoring, Breast Cancer
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer…
- Trial name
- ARCHE (NCT07292207)
- Testing
- Abemaciclib 150 MG Oral Tablet
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Nagoya City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.